

## Company Announcement

### **Nykode Therapeutics – Invitation to Capital Markets Day in New York on September 20, 2023**

- *Management to host a Capital Markets Day at Thompson Central Park New York on September 20, 2023 from 10:00 a.m.-1.30 p.m. ET / 4:00-7:30 p.m. CET.*
- *Highlights to be covered include recent developments within our pipeline of innovative cancer vaccines, with a spotlight on the differentiating factors of our Nykode technology platform and our leading assets, VB10.16 (wholly owned) and VB10.NEO (in collaboration with Genentech).*
- *Guest speaker Dr. Bradley Monk, VP and Member of Board of Directors GOG-Foundation, will provide an insight in the treatment landscape for cervical cancer and perspectives on VB10.16.*
- *The event is a live, virtual event with the possibility for physical attendance. The event can be followed via a live video webcast with access to the presentation slides from the Company's website.*

Oslo, Norway, September 7, 2023 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, invites to a Capital Markets Day for analyst and investors at the Thompson Central Park New York on September 20, 2023 from 10:00 a.m.-1:30 p.m. ET / 4:00-7:30 p.m. CET. The event will be hosted as a live, virtual event, with the possibility for physical attendance. The event can be followed via a live video webcast with access to the presentation slides from the Company's website.

The Capital Markets Day will feature Nykode's Executive Management Team who will provide an update on the development and future potential of Nykode's business, as well as a deep dive into our strategic vision. During this event, we will unveil recent developments within our pipeline of innovative cancer vaccines with a spotlight on the differentiating factors of our Nykode technology platform and our leading assets, VB10.16 (wholly owned) and VB10.NEO (in collaboration with Genentech, a member of the Roche Group).

Our agenda also features a presentation by Dr. Bradley Monk, VP and Member of the Board of Directors of the GOG-Foundation, who will provide insight in the ever-evolving treatment landscape for cervical cancer and perspectives on VB10.16.

For a comprehensive overview of our agenda and additional details, please refer to the full schedule attached hereto.

The live and archived webcast of the presentation can be accessed in the Investors section of the Company's website: <https://nykode.com/investors/financial-reports-and-presentations>



Physical attendance requires registration. To register for the physical event, please send an email to Alexandra Deschner, Head of IR, e-mail: [ir@nykode.com](mailto:ir@nykode.com) by Thursday September 14, 2023.

Nykode will also host a similar Capital Markets Day in Oslo, Norway on September 27, 2023. Details and agenda for this event will follow in due course.

#### **Event details:**

Date and time: September 20, 2023 from 10:00 a.m.-1:30 p.m. ET / 4:00 p.m.-7:30 p.m. CET

Location: Thompson Central Park New York, 119 West 56th Street, New York

Webcast and replay: <https://nykode.com/investors/financial-reports-and-presentations>

Presentation material: <https://nykode.com/investors/financial-reports-and-presentations>

#### **About Nykode Therapeutics**

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies for the treatment of cancer, infectious diseases and autoimmune diseases. Nykode's modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which have been shown to induce broad, strong and long-lasting antigen specific immune responses and elicit efficacious clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus (HPV)-16 induced malignancies which demonstrated positive efficacy and safety results from its Phase 2 trial for the treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of the Roche Group.

The Company's partnerships include Roche and Genentech within oncology and a multi-target collaboration with Regeneron within oncology and infectious diseases.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics may be found at <http://www.nykode.com>.

#### **Forward-looking statements for Nykode Therapeutics**

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.



**Contact for Nykode Therapeutics ASA:**

Alexandra Deschner, Head of IR  
Nykode Therapeutics ASA  
[IR@nykode.com](mailto:IR@nykode.com)

**Nykode Therapeutics ASA**

Oslo Science Park  
Gaustadalléen 21  
N-0349 Oslo, Norway